JAK2 and ovarian cancer: Consistent with the ascites-derived tumor cells, treatment with paclitaxel resulted in the activation of the JAK2/STAT3 pathway in the ovarian cancer HEY cell line, resulting in a marked increase of both phosphorylated αSTAT3 (~86 kDa) and βSTAT3 (79 kDa) at two and three days post-treatment by Western blot (Figure 5).